Genetics of drug resitant tuberculosis

Thorax

Volumn 53, Issue 9, 1998, Pages 793-797

  Telenti, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; METRONIDAZOLE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

BACTERIAL MUTATION; DRUG EFFICACY; GENETICS; HUMAN; MULTIDRUG RESISTANCE; MYCOBACTERIUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; DRUG EFFECT; MUTATION; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0031679252     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.9.793     Document Type: Review

References (66)

1. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997;24(Suppl 1):S121-30.
2. Mendez AP, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9.
3. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994;264: 382-8.
4. Kwon HH, Tomioka H, Saito H. Distribution and characterization of β-lactamases of mycobacteria and related organisms. Tubercle Lung Dis 1995;76:141-8.
5. Heym B, Honoré N, Truffot-Pernot C, et al. Implications of multidrug resistance for the future of short course chemotherapy of tuberculosis: a molecular study. Lancet 1994; 344:293-8.
6. Lipshutz RJ, Morris D, Chee M, et al. Using oligonucleotide probe arrays to access genetic diversity. BioTechniques 1995; 19:442-7.
7. Piatek AS, Tygi S, Telenti A, et al. Molecular beacon sequence analysis: a novel approach to the detection of drug resistance in Mycobacterium tuberculosis. Nature Biotech 1998;16:359-63.
8. Sacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M tuberculosis. Res Microbiol 1996;147:36-13.
9. Heym B, Alzari PM, Honoré N, et al. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995;15:235-45.
10. Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992;358:501-3.
11. Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-30.
12. Telenti A, Honoré N, Bernasconi C, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997;35:719-23.
13. Dessen A, Quemard A, Blanchard JS, et al. Crystal structure and function of the isoniazide target of Mycobacterium tuberculosis. Science 1995;267:1638-41.
14. Rozwarski DA, Grant GA, Barton DHR, et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998;279:98-102.
15. Wilson TM, Collins DM, ahpC, a gene involved in isoniazid resistance of the Mycobacterium tuberculosis complex. Mol Microbiol 1996;19:1025-34.
16. Deretic V, Philipp W, Dhandayuthapani S, et al. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to isoniazid. Mol Microbiol 1995;17:889-900.
17. Sreevatsan S, Pan X, Zhang Y, et al. Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities. Antimicrob Agents Chemother 1997;41:600-6.
18. Mdluli K, Slayden RA, Zhu YQ, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998;280:1607-10.
19. Miesel L, Weisbrod TR, Marcinkeviciene JA, et al. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J Bacteriol 1988;180:2459-67.
20. Chen P, Bishai WR. Novel selection for isoniazid resistance genes identifies nicotinamide-binding proteins of M tuberculosis - implications for INH resistance. ASM Conference on Tuberculosis: Past, Present and Future 1997: Abstract B-36.
21. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
22. Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol 1996;147:48-52.
23. Williams DL, Waguespack C, Eisenach K, et al. Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob Agents Chemother 1994;38:2380-6.
24. Guerrero C, Stockman L, Bodmer T, et al. Evaluation of the rpoB in rifampin-susceptible and resistant Mycobacterium avium and M intracellulare. J Antimicrob Chemother 1994;33:661-3.
25. Dabbs ER, Yazawa K, Mikami Y, et al. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 1995;39:1007-9.
26. Quan S, Venter H, Dabbs ER. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997;41:2456-60.
27. Finken M, Kirschner P, Meier A, et al. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudo-knot. Mol Microbiol 1993;9:1239-46.
28. Honoré N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994;38:238-42.
29. Meier A, Sander P, Schaper KJ, et al. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2452-4.
30. Telenti A, Philipp W, Sreevatsan S, et al. The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine 1997;3:567-70.
31. Belanger AK, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci USA 1996;93:11919-24.
32. Sreevatsan S, Stochbauer KE, Pan X, et al. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 1997;41: 1677-81.
33. Alcaide F, Pfyffer GE, Telenti A. The role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob Agents Chemother 1997;41:2270-3.
34. Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Medicine 1996;2:662-7.
35. Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997;41: 540-3.
36. Sreevatsan S, Pan X, Zhang Y, et al. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob Agents Chemother 1997;41:636-40.
37. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial infections. Clin Infect Dis 1997;25:1213-21.
38. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:1554-8.
39. Takiff HE, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-80.
40. Cambau E, Sougakoff W, Basson M, et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994;170:479-83
41. Takiff HE, Cimino M, Musso CM, et al. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc Natl Acad Sci USA 1996;93:362-6.
42. Kocagoz T, Hackbarth CJ, Unsal I, et al. Gyrase mutations in laboratory selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996;40:1768-74.
43. Lincoln EM. Epidemics of tuberculosis. Adv Tuberc Res 1965;14:157-210.
44. Reves R, Blakey D, Snider Jr DE, et al. Transmission of multiple drug-resistant tuberculosis: report of a school and community outbreak. Am J Epidemiol 1981;113:423-35.
45. van Embden JDA. Molecular epidemiology of tuberculosis. ASM Conference on Tuberculosis: Past, Present and Future 1997: State of the art lecture.
46. Ordway DJ, Sonnenberg MG, Donahue SA, et al. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect Immun 1995;63:741-3.
47. Wilson TM, de Lisle GW, Collins DM. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 1995;15:1009-15.
48. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-11.
49. Telzak EE, Sepkowitz K, Medard F, et al. Durable remission after successful treatment of multidrug-resistant tuberculosis among HIV-negative patients. 35th Annual Meeting of the Infectious Diseases Society of America 1997: Abstract 63.
50. Nivin B, Munsiff SS, Fujiwara PI. Multidrug-resistant tuberculosis among health care workers in New York city. 35th Annual Meeting of the Infectious Diseases Society of America 1997: Abstract 315.
51. Bodmer T, Zürcher G, Imboden I, et al. Molecular basis of rifabutin susceptibility in rifampicin resistant M tuberculosis. J Antimicrob Chemother 1995;35:345-8.
52. Moghazeh SL, Pan X, Arain T, et al. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM 1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother 1996;40:2655-7.
53. Rastogi N, Seng Goh K, David HL. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother 1990;34: 759-64.
54. Khoo KH, Douglas E, Azadi, et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. J Biol Chem 1996; 271:28682-90.
55. Johnson JD, Hand WL, Francis JB, et al. Antibiotic uptake by alveolar macrophages. J Lab Clin Med 1980;95:429.
56. Mdluli K, Swanson J, Fischer E, et al. Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium. Mol Microbiol 1998;27:1223-33.
57. Chambers HF, Kocagoz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis 1998;26:874-7.
58. Mor N, Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997; 41:2035-6.
59. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994;330:1348-55.
60. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon gamma receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996;335:1956-61.
61. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-5.
62. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon gamma receptor gene and susceptibility to mycobacterial infection. N Engl JMed 1996;335:1941-9.
63. Barbachyn MR, Hutchinson DK, Brickner SJ, et al. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996;39:680-5.
64. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel osazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839-15.
65. Slayden RA, Lee RE, Armour JW, et al. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996; 40:2813-9.
66. Cole ST. Why sequence the genome of Mycobacterium tuberculosis. Tubercle Lung Dis 1996;77:486-90.